MilleGen and LFB to develop MAbs

Published: 23-Mar-2007
Sustainability Research & Development

MilleGen, a French biopharmaceutical company focused on Directed Molecular Evolution (DME), and LFB, a leading pharmaceutical supplier to French hospitals, are to design a new generation of recombinant monoclonal antibodies (MAbs).


MilleGen, a French biopharmaceutical company focused on Directed Molecular Evolution (DME), and LFB, a leading pharmaceutical supplier to French hospitals, are to design a new generation of recombinant monoclonal antibodies (MAbs).

In order to achieve this, MilleGen and LFB will work to improve the MAbs pharmacokinetics and effectors functions, which play a key role in their therapeutic capacity.

The deal brings together MilleGen's DME platform Mutagen and LFB's knowhow and expertise in therapeutic antibody discovery and development. MilleGen will apply its Mutagen technology to genetically engineer the Fc region of the antibody as a first phase of the project. The second step will involve LFB conducting pre-clinical evaluation of antibody candidates, in particular in the field of oncohematology.

The project led by MilleGen and LFB will also include an academic laboratory (Inserm U858, Toulouse, France), involved in the molecular and cellular engineering of recombinant antibodies.

Both partners obtained grants from the French government for this r&d project. Financial terms and conditions were not disclosed.

See more

You may also like

Manufacturing

Sapio Sciences introduces world’s first 3rd-generation ELN

Read more
Sapio ELaiN is an AI-powered lab notebook designed to act as a scientific collaborator

Trending Articles

  1. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  2. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  3. Servier acquires potential treatment for Fragile X syndrome KER-0193, a novel, orally bioavailable small molecule, was granted orphan drug and rare paediatric drug designation by the US FDA
  4. NICE recommends enfortumab vedotin with KEYTRUDA for adults in England/Wales with untreated metastatic urothelial cancer The results from the Phase III study EV-302/KN-A39 showed nearly a doubling of survival rates in patients compared with those who received platinum-based chemotherapy, which is the current standard of care in the UK
  5. Ecolab and SCG sign MOU to enhance business competitiveness and drive ESG progress This 5-year MOU underscores how collaboration can turn sustainability commitments into measurable outcomes, accelerating the journey toward Net Zero while strengthening cross-industry competitiveness

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Manufacturing

Sapio Sciences introduces world’s first 3rd-generation ELN

Sapio ELaiN is an AI-powered lab notebook designed to act as a scientific collaborator
Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

New SOLAR CEMNEX analyser offers advanced compliance and connectivity features
Research & Development

Genoskin raises $8.7m in its first funding round to advance its ethical, human-based alternatives to animal testing

The financing will drive Genoskin’s next phase of growth, with a view to scaling up operations in both the US and France
Manufacturing

L.B. Bohle to showcase machines for OSD, food and nutraceuticals at PACK EXPO 2025

Company to present advanced blending, particle sizing and coating technologies at Las Vegas event
Drug Delivery

Tiziana receives grant for intranasal anti-CD3 monoclonal antibody therapy for spinal cord injury

The US Department of Defense awarded the biotechnology company a research grant to study the use of intranasal anti-CD3 therapy in traumatic spinal cord injury (SCI)
Regulatory

Novo Nordisk’s oral semaglutide scores EU approval for cardiovascular benefits

Rybelsus is now the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Manufacturing

Anton Paar launches next-generation rheometers for unmatched precision

New instrument series redefines possibilities in rheological testing and analysis
Subscribe now